Press Releases Roche Holding AG OTC Markets

Equities

RHHBF

CH0012032113

Market Closed - OTC Markets Other stock markets 03:13:03 2024-07-15 pm EDT			5-day change	1st Jan Change
320 ^USD	+6.67%		+5.96%	+2.89%

08:35am	Roche Obesity Pill Achieves Positive Results in Early-Stage Trial -- Update	DJ
08:13am	Roche reports positive early results in obesity drug trial	RE

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity	01:11am	BU
Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)	Jul. 08	BU
FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss	Jul. 05	BU
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer	Jul. 04	BU
Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma	Jun. 15	BU
Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk	Jun. 07	BU
FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation	May. 29	BU
Roche and Hitachi High-Tech extend their long-standing partnership	May. 28	AQ
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation	May. 21	BU
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity	May. 16	BU
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer	Apr. 18	BU
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS	Apr. 17	BU
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study	Apr. 15	BU
Invitation to Roche's First Quarter Sales 2024 Presentation	Mar. 25	AQ
Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024	Mar. 12	AQ
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure	Mar. 06	AQ
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies	Feb. 25	BU
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies	Feb. 19	AQ
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies	Feb. 16	BU
AlzeCure Pharma broadcasts live expert event on Alzheimer's around highly current gamma-secretase modulators	Feb. 12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 11:50 am EDT

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am EST